Cara Therapeutics IncNASDAQ:CARANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.2881
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.2801/ 21
- Ask / Lots0.2990/ 96
- Open / Previous Close--- / 0.2881
- Day Range---
- 52 Week Range
- Volume42
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CARA |
|---|---|---|
| 09:32 ET | 2655 | 0.285 |
| 09:33 ET | 6891 | 0.29 |
| 09:42 ET | 3015 | 0.288126 |
| 09:44 ET | 730 | 0.288126 |
| 09:50 ET | 10000 | 0.2855 |
| 09:51 ET | 10000 | 0.2855 |
| 09:55 ET | 600 | 0.2945 |
| 09:57 ET | 491 | 0.2928 |
| 10:08 ET | 1000 | 0.287258 |
| 10:09 ET | 300 | 0.2948 |
| 10:13 ET | 3400 | 0.2903 |
| 10:22 ET | 32025 | 0.29 |
| 10:24 ET | 100 | 0.295 |
| 10:26 ET | 5000 | 0.2857 |
| 10:29 ET | 102 | 0.2862 |
| 10:31 ET | 300 | 0.295 |
| 10:36 ET | 160 | 0.2857 |
| 10:45 ET | 100 | 0.286 |
| 10:51 ET | 10100 | 0.29255 |
| 10:56 ET | 1000 | 0.293936 |
| 11:09 ET | 241 | 0.2925 |
| 11:14 ET | 11232 | 0.29 |
| 11:16 ET | 200 | 0.29 |
| 11:18 ET | 10500 | 0.29 |
| 11:20 ET | 150 | 0.2925 |
| 11:30 ET | 100 | 0.2901 |
| 11:32 ET | 282 | 0.292079 |
| 11:34 ET | 3500 | 0.29 |
| 11:36 ET | 2000 | 0.29259 |
| 11:38 ET | 100 | 0.29 |
| 11:41 ET | 1600 | 0.2916 |
| 11:45 ET | 100 | 0.2905 |
| 11:48 ET | 4909 | 0.298 |
| 11:50 ET | 200 | 0.291 |
| 11:57 ET | 100 | 0.294 |
| 12:08 ET | 232 | 0.297899 |
| 12:10 ET | 199 | 0.297 |
| 12:12 ET | 10150 | 0.298 |
| 12:14 ET | 21167 | 0.2932 |
| 12:15 ET | 15229 | 0.2871 |
| 12:17 ET | 400 | 0.2905 |
| 12:19 ET | 5400 | 0.2878 |
| 12:24 ET | 200 | 0.295 |
| 12:32 ET | 200 | 0.2872 |
| 12:42 ET | 183 | 0.297699 |
| 12:46 ET | 618 | 0.297599 |
| 12:48 ET | 400 | 0.2976 |
| 12:51 ET | 1575 | 0.2964 |
| 12:53 ET | 100 | 0.295603 |
| 12:57 ET | 300 | 0.2977 |
| 01:09 ET | 250 | 0.2973 |
| 01:11 ET | 100 | 0.297 |
| 01:18 ET | 307 | 0.2976 |
| 01:24 ET | 200 | 0.2977 |
| 01:26 ET | 4600 | 0.289 |
| 01:36 ET | 100 | 0.2881 |
| 01:42 ET | 367 | 0.2976 |
| 01:47 ET | 100 | 0.297 |
| 01:51 ET | 54122 | 0.288 |
| 01:54 ET | 1100 | 0.29 |
| 01:58 ET | 100 | 0.289 |
| 02:00 ET | 1593 | 0.289971 |
| 02:02 ET | 2800 | 0.291 |
| 02:05 ET | 500 | 0.2925 |
| 02:20 ET | 100 | 0.2919 |
| 02:23 ET | 200 | 0.2975 |
| 02:32 ET | 400 | 0.297 |
| 02:38 ET | 734 | 0.2926 |
| 02:45 ET | 200 | 0.297 |
| 02:48 ET | 36534 | 0.29 |
| 02:50 ET | 100 | 0.29 |
| 02:57 ET | 100 | 0.2902 |
| 02:59 ET | 100 | 0.2925 |
| 03:03 ET | 1507 | 0.2925 |
| 03:10 ET | 1627 | 0.2884 |
| 03:12 ET | 2026 | 0.2883 |
| 03:15 ET | 544 | 0.2883 |
| 03:17 ET | 360 | 0.2926 |
| 03:21 ET | 281 | 0.2968 |
| 03:30 ET | 300 | 0.297 |
| 03:32 ET | 7282 | 0.298 |
| 03:48 ET | 335 | 0.2979 |
| 03:50 ET | 7500 | 0.2979 |
| 03:57 ET | 3231 | 0.2881 |
| 04:00 ET | 8041 | 0.2881 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cara Therapeutics Inc | 15.8M | -0.2x | --- |
Turnstone Biologics Corp | 11.7M | -0.2x | --- |
Viaderma Inc | 12.3M | 0.0x | --- |
SQZ Biotechnologies Co | 825.8K | 0.0x | --- |
HOOKIPA Pharma Inc | 29.9M | -0.6x | --- |
Predictive Technology Group Inc | 149.8K | 0.0x | --- |
Company Information
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Contact Information
- Headquarters
- 400 Atlantic Street, Suite 500STAMFORD, CT, United States 06901
- Phone
- 203-406-3700
- Fax
- 203-567-1510
Executives
- Independent Chairman of the Board
- Martin Vogelbaum
- President, Chief Executive Officer, Director
- Christopher Posner
- Chief Financial Officer
- Ryan Maynard
- Chief Compliance Officer, General Counsel, Secretary
- Scott Terrillion
- Director
- Helen Boudreau
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.8M |
|---|---|
Revenue (TTM) | $8.7M |
Shares Outstanding | 54.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.63 |
EPS | $-1.75 |
Book Value | $1.05 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 1.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,063.21% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
